Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373958 · ClinicalTrials.gov registry record · Phase 3
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
A Phase 3 study of Vaccines, Pneumococcal, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 666
- Enrollment target
- 20
- Study locations
NCT00373958: Completed Phase 3 study of Vaccines, Pneumococcal, sponsored by Pfizer.
NCT00373958 is a Phase 3 study of Vaccines, Pneumococcal that has completed, run by Pfizer. The registered enrollment target is 666 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00373958, a Phase 3 study of Vaccines, Pneumococcal, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 666 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Primary Outcome
Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Conditions Studied
Interventions
- BIOLOGICAL 13 valent pneumococcal conjugate vaccine
- BIOLOGICAL 7vPnc pneumococcal conjugate vaccine
Study Locations (20)
California
- - Downey
- - Fontana
- - Loma Linda
- - Paramount
- - Riverside
Arkansas
- - Fayetteville
- - Jonesboro
- - Little Rock
Kentucky
- - Bardstown
- - Louisville
- - Louisville
Georgia
- - Marietta
- - Woodstock
Illinois
- - Chicago
- - Park Ridge
Colorado
- - Centennial
Connecticut
- - Norwich
Florida
- - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 666 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00373958 record still lists
NCT00373958 is an interventional study that assigns participants to a tested intervention. The registered 666 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Vaccines, Pneumococcal appearing as the primary indexed condition, and to 2 interventions - of which 13 valent pneumococcal conjugate vaccine is the first listed.
NCT00373958 names 20 study sites across 10 states, led by California, Arkansas, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00373958 about?
NCT00373958 is a clinical study titled "Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine". The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
What is the current status of trial NCT00373958?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 666 participants. The study started on 2006-09. Estimated completion is 2008-06.
What conditions does trial NCT00373958 study?
This clinical trial studies the following conditions: Vaccines, Pneumococcal.
What interventions are being tested in trial NCT00373958?
The interventions under investigation include: 13 valent pneumococcal conjugate vaccine (BIOLOGICAL), 7vPnc pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00373958?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373958 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccines, Pneumococcal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00373958's enrollment target sits among peer trials
666 551st of 2000 higher than 1,449 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia